Nuvectis reports Q2 2022 net loss of $3.6M; cash $13.6M; pipeline advances

Nuvectis Pharma, Inc.

2022-Q2 EPS reported -$0.57

Cash and investments $13.6M at June 30, 2022, up from $5.7M at Dec 31, 2021, driven by IPO.
Net loss of $3.6M for Q2 2022, narrowed from $5.9M in Q2 2021 due to lower R&D and G&A.
NXP800 Phase 1a dose-escalation ongoing; Phase 1b expansion expected Q1 2023; FDA cleared IND, U.S. and U.K. enrolling.
NXP900 IND-enabling studies on track for 2022 completion; preclinical data in medulloblastoma presented.
Completed $15.9M private placement in August 2022, extending cash runway into H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.